touchCONGRESS

Exploring the latest data on new and emerging treatments for the improvement of outcomes in higher-risk MDS and newly diagnosed AML

Access to this content is not permitted for healthcare professionals based in the US and UK.

Back to Education
Haematological Malignancies Watch Time: 64 mins

touchCONGRESS Exploring the latest data on new and emerging treatments for the improvement of outcomes in higher-risk MDS and newly diagnosed AML

Watch this two-part activity exploring recent developments around the treatment of higher-risk MDS and newly diagnosed AML. Filmed following the EHA2021 Virtual Congress.

Part 1: Watch haematological cancer expert Prof. Uwe Platzbecker review key data from the EHA2021 Virtual Congress Watch Now
Part 2: Choose from leading experts who discuss what these data mean for global and regional practice Select An Interview

 

  • Part 1: Data Review
Next Chapter
Introduction
Mechanism of action and key clinical data for emerging treatments for higher-risk MDS
Current treatments and novel approaches for newly diagnosed AML, including management options when intensive induction therapy is not suitable
Current and future potential of immunotherapy and the use of MRD monitoring in MDS and AML
Video Player Controls:
 
Leave Feedback
  • Part 2: Expert Interviews
Leave Feedback
Prof. Uwe Platzbecker
Watch Time: 08:46 Medical Clinic of Hematology, University Hospital Leipzig, Leipzig, Germany

Uwe Platzbecker considers the latest data on new and emerging treatments for the improvement of outcomes in higher-risk MDS and newly diagnosed AML from the EHA2021 Virtual Congress.
 
 
Leave Feedback
Prof. Valeria Santini
Watch Time: 19:13 Careggi University Hospital, University of Florence, Florence, Italy

Valeria Santini considers the latest data on new and emerging treatments for the improvement of outcomes in higher-risk MDS and newly diagnosed AML from the EHA2021 Virtual Congress.
 
 
Leave Feedback
Prof. Andrew Wei
Watch Time: 13:09 Alfred Hospital and Monash University, Melbourne, Australia

Andrew Wei considers the latest data on new and emerging treatments for the improvement of outcomes in higher-risk MDS and newly diagnosed AML from the EHA2021 Virtual Congress.
 
Leave Feedback
Please Select A Video:
Prof. Uwe Platzbecker
 Medical Clinic of Hematology, University Hospital Leipzig, Leipzig, Germany Watch Time: 08:46 Translations available:
Watch Video
Prof. Valeria Santini
 Careggi University Hospital, University of Florence, Florence, Italy Watch Time: 19:13 Translations available:
Watch Video
Prof. Andrew Wei
 Alfred Hospital and Monash University, Melbourne, Australia Watch Time: 13:09 Translations available:
Watch Video
Leave Feedback
Overview & Learning Objectives
Overview

Stay up to date with the  latest data on new and emerging treatments for the improvement of outcomes in higher-risk myelodysplastic syndromes (MDS) and newly diagnosed acute myeloid leukaemia (AML) in this two-part activity. This activity was filmed following the EHA2021 Virtual Congress.

Learning Objectives

After watching this activity, participants should be better able to:

  • Recall the mechanisms of action and key clinical data for emerging treatments for higher-risk MDS
  • Evaluate current treatments and novel approaches for newly diagnosed AML, including management options when intensive induction therapy is not suitable
  • Discuss the current and future potential of immunotherapy and the use of measurable residual disease (MRD) monitoring in MDS and AML
Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights
Register For Free Now
This Activity Is Funded By:

An independent medical education grant from Novartis.
This activity is provided by touchIME.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

This content is intended only for healthcare professionals.

Launch date: 20 July 2021.

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchCONGRESS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

* = Mandatory Field

Feedback Close
Feedback

Thank you for your feedback.

Back to Activity
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72